Esperion Therapeutics, Inc. Presents Full Results Of Phase 2 Clinical Study Demonstrating That ETC-1002 Lowered LDL-C By An Average Of 32 Percent And Was Well Tolerated In Patients With Hypercholesterolemia And History Of Statin Intolerance
Published: Nov 18, 2013
DALLAS & PLYMOUTH, Mich.--(BUSINESS WIRE)--Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced full results of a Phase 2 clinical study of its lead product candidate ETC-1002 in patients with hypercholesterolemia and a history of statin intolerance. The study, ETC-1002-006, met its primary endpoint, demonstrating that ETC-1002 significantly lowered LDL-C compared to placebo by an average of 32 percent and was well tolerated. The data were presented today in an oral presentation at the 2013 Scientific Sessions of the American Heart Association in Dallas by principal investigator Paul D. Thompson, M.D. Esperion previously announced positive topline results from this study in June 2013.
Help employers find you! Check out all the jobs and post your resume.